The kit consisted of purified polyclonal antibody and monoclonal detection antibody highly specific for big ET-1. Furthermore, plasma big ET-1 levels decreased significantly after radical resection of the primary tumor and individuals with postoperative recurrence experienced significantly higher plasma big ET-1 levels than that of individuals without recurrence. Finally, the survival rate of individuals with higher plasma big ET-1 concentrations (>4.3 pg/ml) was significantly lower than that of patients with lower level ( 4.3 pg/ml). Multivariate regression analysis showed that plasma big ET-1 level is an impartial prognostic factor for survival in patients with ESCC. == Conclusion == Plasma big ET-1 level in ESCC patients may reflect malignancy and predict tumor recurrence and patient survival. Therefore, the preoperative plasma big ET-1 levels may be a clinically useful biomarker for choice of multimodality therapy in ESCC patients. == Background == The incidence of esophageal malignancy shows a striking geographic variance in the world: a 20-fold variation is usually observed between high-risk China and low-risk western Africa[1]. Recently, improvements in surgical techniques and peri-operative management significantly improved the outcome of patients with squamous cell carcinoma of the esophagus. However, the overall survival remains poor and the five 12 months survival rate remains below 30 percent in patients with esophageal malignancy after a curative esophagectomy[2-4]. Many results[5-8] exhibited the prognosis in patients with esophageal malignancy mainly depends on tumor stage, but other multiple factors, including age, gender, the size of tumor and some molecular markers, will influence tumor response to therapy. Accurate prognostic factor is essential for selecting patients who are suitable AG-120 (Ivosidenib) for combined-modality therapy. The use of circulating prognostic biomarkers is usually a convenient way to achieve the objective[9]. AG-120 (Ivosidenib) Endothelins(ETs), including ET-1, ET-2 Rabbit Polyclonal to OR13C4 and ET-3, are small 21-residue peptides[10]. There are at least two receptor subtypes, endothelin A receptors(ETAR) and endothelin B receptors(ETBR), belonging to the family of G-protein-linked receptors with seven transmembrane-spanning domains[11]. The ET-1 gene encodes a precursor peptide, preproendothelin-1, which is usually cleaved by a neutral endopeptidase to form proendothelin-1 or big ET-1. Due to a low circulating concentration and a short plasma half-life (about 1.5 min), measurement of plasma ET-1 concentrations has proven to be difficulty. Big ET-1 is usually a stable peptide with a plasma half-life of 30 minutes, making the measurement of plasma big ET-1 concentrations a sensitive indication of endothelin system activation[12,13]. Recent studies [14-18] have suggested that ET-1 may play an important role in tumorigenesis, tumor progression and metastasis presumably by numerous mechanisms, including mitogenesis, inhibition of apoptosis, angiogenesis and mediating extracellular matrix degradation. According to our previous study[19], ET-1 can increase the invasive ability of human esophageal AG-120 (Ivosidenib) malignancy cells. However, it is unclear about prognostic significance of preoperative plasma big ET-1 in patients with ESCC. In this study, we evaluated: 1)plasma big ET-1 levels in ESCC patients and in healthy controls, 2) its correlation with clinicopathologic features, tumor recurrence and patient survival, and 3) the effect of surgery on AG-120 (Ivosidenib) plasma big ET-1 levels. == Methods == == Patient Selection == The study population consists of 122 consecutive patients who underwent radical resection at our hospital between March of 2000 and August of 2002. All patients had been confirmed as esophageal squamous cell carcinoma by postoperative histopathologic assessment. Tumor stage was classified by the routine histopathologic assessment according to the UICC TNM staging system [20]. Patients who experienced received chemotherapy and/or radiotherapy before surgery were excluded from the study. Patients with co-morbid conditions that are associated with elevated ET-1, such as hypertension, cardiac failure, myocardial infarction and rheumatic diseases, were excluded. Moreover, 122 patients were asked about their habits of smoking and drinking. They were divided into three groups stratified by the number of cigarettes per day(cps) defined as non-smoker(have not smoked yet or very rarely tried to smoke), light-smoker(less than 20 cps) and heavy-smoker(more than 20 cps). And the patients were also divided into three groups stratified by ethanol intake levels defined as nondrinker (less than 1 g/day), light-drinker (150 g/day) and heavy-drinker (more than 50 g/day). Fourteen patients which were heavy smokers and/or drinkers were excluded.